Crosstalk between oncolytic viruses and autophagy in cancer therapy

• Published in: Biomedicine & pharmacotherapy Vol. 134; p. 110932
• Main Authors: Jin, Ke-Tao, Tao, Xiao-Hua, Fan, Yi-Bin, Wang, Shi-Bing
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.02.2021; Elsevier
• Subjects: Autophagic cell death; Autophagy; Cancer; Immunogenic cell death; Oncolytic virus; Autophagic cell death; Oncolytic virus; Autophagy; Immunogenic cell death; Cancer
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2020.110932

[Display omitted] Oncolytic viruses have attracted attention as a promising strategy in cancer therapy owing to their ability to selectively infect and kill tumor cells, without affecting healthy cells. They also exert their anti-tumor effects by releasing immunostimulatory molecules from dying cancer cells. Several regulatory mechanisms, such as autophagy, contribute to the anti-tumor properties of oncolytic viruses. Autophagy is a conserved catabolic process in responses to various stresses, such as nutrient deprivation, hypoxia, and infection that produces energy by lysosomal degradation of intracellular contents. Autophagy can support infectivity and replication of the oncolytic virus and enhance their anti-tumor effects via mediating oncolysis, autophagic cell death, and immunogenic cell death. On the other hand, autophagy can reduce the cytotoxicity of oncolytic viruses by providing survival nutrients for tumor cells. In his review, we summarize various types of oncolytic viruses in clinical trials, their mechanism of action, and autophagy machinery. Furthermore, we precisely discuss the interaction between oncolytic viruses and autophagy in cancer therapy and their combinational effects on tumor cells.